Temodar and olaparib for glioblastoma – pro
There are some early studies on its combination. A case report by File et al presented a case in 2020 reported a case in which tumor genomic profiling and germline results provided a rationale for the addition of olaparib to standard therapy. The patient had a remarkable response, with an ongoing near-total absence of radiographic disease 2 years beyond diagnosis. M Kushnirsky et al presented a retrospective review in 2022 and concluded that the addition of PARP inhibitors to temozolomide may be an effective treatment for recurrent gliomas. Further investigations of this therapy, particularly in the IDH-mt population, is warranted.
D.Filer et al, Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With
ATM-Mutated Glioblastoma and MSH6-Deficient Lynch SyndromeJCO Precision Oncology no. 4 (2020) 841-847
Marina Kushnirsky, Andrew Lin, Alexandra Miller, Igor Gavrilovic, Craig Nolan, Elena Pentsova, Ingo Mellinghoff, Thomas Kaley, Lauren Schaff, Concurrent Olaparib and Temozolomide for Recurrent Glioma (P5-9.005). Neurology May 03, 2022; 98 (18 Supplement)
NCCN CNS Cancers 2023